Cart123 Cells
Acute Myeloid Leukemia, Pediatric
University of PennsylvaniaCell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
52 Active assets in the Acute Myeloid Leukemia, Pediatric cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ETOPOSIDE Joanna Yi | Phase 3 | BBB |
Cytosin-Arabinosid Children's Oncology Group | Phase 3 | BBB |
METHOTREXATE Children's Oncology Group | Phase 3 | BBB |
FILGRASTIM National Cancer Institute (NCI) | Phase 3 | BBB |
Cyclophosphamide Fred Hutchinson Cancer Center | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Cart123 Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →